Monte Financial Group LLC Sells 327 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Monte Financial Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,782 shares of the biopharmaceutical company’s stock after selling 327 shares during the period. Monte Financial Group LLC’s holdings in Pfizer were worth $531,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Pfizer by 7.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 63,397 shares of the biopharmaceutical company’s stock valued at $2,289,000 after acquiring an additional 4,652 shares during the last quarter. Altavista Wealth Management Inc. lifted its stake in shares of Pfizer by 7.3% in the 3rd quarter. Altavista Wealth Management Inc. now owns 116,631 shares of the biopharmaceutical company’s stock valued at $4,191,000 after acquiring an additional 7,963 shares during the last quarter. D.A. Davidson & CO. lifted its stake in shares of Pfizer by 4.5% in the 3rd quarter. D.A. Davidson & CO. now owns 382,844 shares of the biopharmaceutical company’s stock valued at $13,756,000 after acquiring an additional 16,497 shares during the last quarter. EFG Asset Management Americas Corp. lifted its stake in shares of Pfizer by 38.5% in the 3rd quarter. EFG Asset Management Americas Corp. now owns 13,029 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 3,621 shares during the last quarter. Finally, Putnam FL Investment Management Co. lifted its stake in shares of Pfizer by 11.9% in the 3rd quarter. Putnam FL Investment Management Co. now owns 189,217 shares of the biopharmaceutical company’s stock valued at $6,799,000 after acquiring an additional 20,067 shares during the last quarter. 71.51% of the stock is owned by institutional investors.

In other news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

PFE traded up $0.04 during midday trading on Tuesday, reaching $36.97. 12,649,260 shares of the company’s stock traded hands, compared to its average volume of 23,265,662. The firm has a fifty day moving average of $36.64 and a two-hundred day moving average of $39.24. The stock has a market capitalization of $205.04 billion, a price-to-earnings ratio of 12.32, a P/E/G ratio of 3.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.68. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. Pfizer’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.

A number of equities research analysts have recently weighed in on PFE shares. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group reissued a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Morgan Stanley lowered their target price on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 price target on shares of Pfizer in a research report on Wednesday, November 6th. Nine equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $44.02.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Balance Sheet

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.